CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its product candidates are also developed for prophylactic vaccines, cancer immunotherapy and other therapeutic areas. The company's lead product candidate is CVnCoV that is in Phase I human clinical trials to protect against coronaviruses, including the SARS-CoV-2 virus. It also develops additional prophylactic vaccine antibiotics, including CV301, which is in Phase II clinical trials for treating non-small cell lung cancer and cervical cancer; CV9202 in preclinical stage for treating melanoma and prostate cancer; and CV8102 preclinical stage for treating breast and pancreatic cancers.
The company's mRNA therapeutics have demonstrated their potential to treat cancers through the triggering of intracellular immune responses. CureVac N.V. operates in the United States, Germany, and internationally. The company was formerly known as Curevac GmbH and changed its name to CureVac N.V. in December 2016.
Latest events on Quartr
Previous Events for CureVac N.V.
United States of America